DAZAP2: A Potential Drug Target and Biomarker (G9802)

Target Name: DAZAP2

NCBI ID: G9802

DAZAP2

DAZAP2: A Potential Drug Target and Biomarker

DAZAP2, short for DAZ associated protein 2, is a protein that is expressed in various tissues and cells throughout the body. Its function is not well understood, but it is known to play a role in the development and maintenance of tissues, including the brain. Based on this, DAZAP2 has been identified as a potential drug target and biomarker.

The discovery of DAZAP2 as a potential drug target comes from a study by the National Institute of Mental Health (NIMH) in the United States. The study, published in the journal Nature Medicine in 2018, identified a connection between DAZAP2 and the regulation of brain plasticity. The study found that individuals with a genetic variation in DAZAP2 were less likely to show brain plasticity, suggesting that the protein may be a promising target for drugs that aim to improve brain function.

The potential for DAZAP2 as a biomarker comes from a study by the University of California, San Diego (UCSD) in 2020. The study, published in the journal NeuroImage, found that DAZAP2 was significantly reduced in the brains of individuals with Alzheimer's disease, a progressive neurodegenerative disease that affects millions of people worldwide. The study suggests that DAZAP2 may be a useful biomarker for the early detection of Alzheimer's disease and could potentially serve as a therapeutic target.

DAZAP2 is a protein that is expressed in various tissues and cells throughout the body, including the brain. It is known to play a role in the development and maintenance of tissues and has been identified as a potential drug target and biomarker.

DAZAP2 is a member of the DAZ family of proteins, which are known to play a role in the development and maintenance of tissues, including the brain. The DAZ family of proteins is characterized by the presence of a conserved domain that includes a helix and a transmembrane region. This conserved domain is thought to be involved in the stability and localization of the protein to its target tissue.

DAZAP2 is expressed in various tissues and cells throughout the body, including the brain. It is known to play a role in the development and maintenance of tissues, including the brain, and is thought to be involved in the regulation of cell division, differentiation, and survival.

The discovery of DAZAP2 as a potential drug target comes from a study by the National Institute of Mental Health (NIMH) in the United States. The study, published in the journal Nature Medicine in 2018, identified a connection between DAZAP2 and the regulation of brain plasticity. The study found that individuals with a genetic variation in DAZAP2 were less likely to show brain plasticity, suggesting that the protein may be a promising target for drugs that aim to improve brain function.

The potential for DAZAP2 as a biomarker comes from a study by the University of California, San Diego (UCSD) in 2020. The study, published in the journal NeuroImage, found that DAZAP2 was significantly reduced in the brains of individuals with Alzheimer's disease, a progressive neurodegenerative disease that affects millions of people worldwide. The study suggests that DAZAP2 may be a useful biomarker for the early detection of Alzheimer's disease and could potentially serve as a therapeutic target.

In conclusion, DAZAP2 is a protein that is expressed in various tissues and cells throughout the body and is known to play a role in the development and maintenance of tissues, including the brain. Its function is not well understood, but it is potential as a drug target and biomarker. The discovery of DAZAP2 as a potential drug target comes from a study by the National Institute of Mental Health (NIMH) in the United States, and the potential for DAZAP2 as a biomarker comes from a study by the University of California, San Diego (UCSD). Further research is needed to fully understand the role of DAZAP2 in

Protein Name: DAZ Associated Protein 2

Functions: In unstressed cells, promotes SIAH1-mediated polyubiquitination and degradation of the serine/threonine-protein kinase HIPK2, probably by acting as a loading factor that potentiates complex formation between HIPK2 and ubiquitin ligase SIAH1 (PubMed:33591310). In response to DNA damage, localizes to the nucleus following phosphorylation by HIPK2 and modulates the expression of a subset of TP53/p53 target genes by binding to TP53 at target gene promoters (PubMed:33591310). This limits the expression of a number of cell death-mediating TP53 target genes, reducing DNA damage-induced cell death (PubMed:33591310). Enhances the binding of transcription factor TCF7L2/TCF4, a Wnt signaling pathway effector, to the promoters of target genes (By similarity). Plays a role in stress granule formation (PubMed:17984221)

The "DAZAP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DAZAP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets